Nodular regenerative hyperplasia of the liver

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

10 events
Mar 2026NURTEC ODT: New indication approved
FDAcompleted
Aug 2025NURTEC ODT: New indication approved
FDAcompleted
May 2025Hepatic Venous Pressure Gradient Versus Endoscopic Ultrasound-Guided Portal Pressure Gradient - Comparative Analysis (HEPCA)

Military University Hospital, Prague — NA

TrialRECRUITING
Mar 2025NURTEC ODT: New indication approved
FDAcompleted
Dec 2024NURTEC ODT: New indication approved
FDAcompleted
Apr 2022NURTEC ODT: New indication approved
FDAcompleted
Mar 2022NURTEC ODT: New indication approved
FDAcompleted
Dec 2021NURTEC ODT: New indication approved
FDAcompleted
May 2021NURTEC ODT: New indication approved
FDAcompleted
Aug 2020NURTEC ODT: New indication approved
FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Nodular regenerative hyperplasia of the liver.
Check the disease page for updates →

Clinical Trial Landscape

No active clinical trials currently recruiting for Nodular regenerative hyperplasia of the liver.
Search all trials →
Search clinical trials for Nodular regenerative hyperplasia of the liver

Recent News & Research

No recent news articles indexed yet for Nodular regenerative hyperplasia of the liver.
Search PubMed for Nodular regenerative hyperplasia of the liver

Browse all Nodular regenerative hyperplasia of the liver news →

Specialist Network

Top 6 by expertise

View all Nodular regenerative hyperplasia of the liver specialists →

Quick Actions